0HG8 Stock Chart & Stats
$396.17
$0.21(0.05%)
At close: 4:00 PM EDT
$396.17
$0.21(0.05%)
Day’s Range― - ―
52-Week Range$274.98 - $450.46
Previous CloseN/A
Volume1.00
Average Volume (3M)494.00
Market Cap
$95.05B
Enterprise Value$115.48B
Total Cash (Recent Filing)$37.85B
Total Debt (Recent Filing)$30.76B
Price to Earnings (P/E)18.7
Beta0.27
Next Earnings
Jan 27, 2027EPS Estimate
2.1Next Dividend Ex-DateN/A
Dividend Yield1.54%
Share Statistics
EPS (TTM)23.48
Shares Outstanding216,055,900
10 Day Avg. Volume1,042
30 Day Avg. Volume494
Financial Highlights & Ratios
PEG Ratio-5.70
Price to Book (P/B)1.77
Price to Sales (P/S)0.39
P/FCF Ratio24.50
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue0.57
Enterprise Value/Gross Profit1.57
Enterprise Value/Ebitda13.01
Forecast
1Y Price Target
$475.92Price Target Upside20.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)28.53
Revenue Forecast (FY)$199.61B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationThe sharp free-cash-flow rebound and strong conversion from earnings provide internal funding for investments, dividends, and other capital priorities. This cash capacity improves resilience across underwriting cycles and supports Carelon expansion without relying excessively on external financing.
Carelon Growth PlatformCarelon adds a services-led growth engine alongside insurance premiums, helping diversify revenue and extend Elevance’s healthcare capabilities to external customers. High retention, new wins, and a broad pipeline indicate that the platform can support recurring growth beyond membership changes.
Integrated Healthcare ValueCombining medical and pharmacy capabilities can produce measurable savings and lower emergency-room use, strengthening the value proposition for members, employers, and health plans. Demonstrated clinical and cost outcomes can support retention, contracting power, and broader adoption of Elevance’s integrated model.
Bears Say
Persistent Margin CompressionMulti-year margin erosion means revenue growth is not translating proportionally into earnings, leaving less buffer against medical-cost volatility. If profitability remains compressed, Elevance may have less flexibility to invest, absorb adverse claims development, or improve returns while maintaining competitive pricing.
Medicaid Cost And Rate PressureWhen reimbursement rates lag healthcare costs, Medicaid margins remain vulnerable even if utilization and care-management actions improve. The expected recovery depends on future rate alignment, while work requirements and membership changes may add acuity uncertainty and prolong pressure on this business.
ACA Risk-pool NormalizationA prolonged ACA risk-pool adjustment can create uncertainty in member mix, risk adjustment, and claims economics across multiple renewal cycles. The shift toward lower-premium bronze plans may pressure profitability and require continued pricing, retention, and underwriting discipline.
Elevance Health News
0HG8 FAQ
What was Elevance Health’s price range in the past 12 months?
Elevance Health lowest share price was $274.98 and its highest was $450.46 in the past 12 months.
What is Elevance Health’s market cap?
Elevance Health’s market cap is $95.05B.
When is Elevance Health’s upcoming earnings report date?
Elevance Health’s upcoming earnings report date is Jan 27, 2027 which is in 92 days.
How were Elevance Health’s earnings last quarter?
Elevance Health released its earnings results on Oct 21, 2026. The company reported $6.99 earnings per share for the quarter, beating the consensus estimate of $4.714 by $2.276.
Is Elevance Health overvalued?
According to Wall Street analysts Elevance Health’s price is currently Undervalued.
Does Elevance Health pay dividends?
Elevance Health pays a Quarterly dividend of $1.72 which represents an annual dividend yield of 1.54%. See more information on Elevance Health dividends here
What is Elevance Health’s EPS estimate?
Elevance Health’s EPS estimate is 2.1.
How many shares outstanding does Elevance Health have?
Elevance Health has 216,055,900 shares outstanding.
What happened to Elevance Health’s price movement after its last earnings report?
Elevance Health reported an EPS of $6.99 in its last earnings report, beating expectations of $4.714. Following the earnings report the stock price went up 0.588%.
Which hedge fund is a major shareholder of Elevance Health?
Currently, no hedge funds are holding shares in GB:0HG8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elevance Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$475.92 (20.13% Upside)
$475.92 (20.13% Upside)
Blogger Sentiment
Bullish
GB:0HG8 Sentiment 77%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth $4.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.57%
12-Months-Change
Fundamentals
Return on Equity
11.59%
Trailing 12-Months
Asset Growth
4.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elevance Health
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
0HG8 Company Deck
0HG8 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Elevance Health reported better-than-expected third-quarter results, raised 2026 adjusted EPS guidance to at least $29, increased its earnings baseline to at least $26.75, raised operating cash flow guidance to at least $6.5 billion, and maintained confidence in at least 12% adjusted EPS growth in 2027. Medicaid cost trends, commercial cost pressures, IDR-related issues, ACA risk-pool normalization, and a non-recurring fourth-quarter tax item remain challenges, but management characterized operating performance and visibility as improving across the enterprise.View all GB:0HG8 earnings summaries0HG8 Stock 12 Month Forecast
Average Price Target
$475.92
▲(20.13% Upside)